Efficacy of Cyclosporine for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy
Completed
Innovative Medical
Phase 4
2006-09-01
The purpose of this study is to evaluate the effect of topical cyclosporine ophthalmic
solution 0.05% (Restasis, Allergan) on the signs and symptoms of dry eye in patients
undergoing LASIK or photorefractive keratectomy (PRK).
Efficacy of Optive Versus Systane Concomitant With Restasis (Cyclosporine A) for the Treatment of Dry Eye Symptoms
Completed
Innovative Medical
Phase 4
2006-11-01
The purpose of this study is to evaluate the efficacy of Optive versus Systane used
concomitantly with topical cyclosporine for the treatment of dry eye.
Will Restasis Eye Drops Increase Your Chance of Having a Successful Surgery?
Completed
Allergan
N/A
2004-03-01
The purpose of this study is to determine whether reducing inflammation of the surface of the
eye with topical Restasis after glaucoma surgery will improve surgical outcomes and increase
patient comfort.
Will Restasis Eye Drops Increase Your Chance of Having a Successful Surgery?
Completed
Wills Eye
N/A
2004-03-01
The purpose of this study is to determine whether reducing inflammation of the surface of the
eye with topical Restasis after glaucoma surgery will improve surgical outcomes and increase
patient comfort.
Efficacy and Safety of a New Multi-dose Lubricant Eye Drop Concomitant With Restasis® (Cyclosporine A) for the Treatment of Dry Eye Symptoms
Completed
Innovative Medical
Phase 4
2006-11-01
To evaluate the efficacy, safety and tolerability of a combination of Optive® Artificial
Tears with Restasis®.The primary hypothesis is that the Ocular Surface Disease Index (OSDI)
score and symptoms will be the same or lower than baseline after treatment in these patients.
The patients will tolerate the combination of Restasis® and Optive® with a low incidence of
clinical adverse events.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
